Annual report
9273.TEDINET S100Z2Z6
Period2025-07-01 → 2026-06-30
Filed2026-09-18
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥24.7bn | 2025-07-01 → 2026-06-30 | Cons. | Net sales |
| Revenue | ¥23.3bn | 2024-07-01 → 2025-06-30 | Cons. | Net sales |
| Revenue | ¥22.1bn | 2023-07-01 → 2024-06-30v | Cons. | Net sales (5-year summary) |
| Revenue | ¥22.1bn | 2022-07-01 → 2023-06-30v | Cons. | Net sales (5-year summary) |
| Revenue | ¥20.4bn | 2021-07-01 → 2022-06-30v | Cons. | Net sales (5-year summary) |
| Operating income | ¥5.5bn | 2025-07-01 → 2026-06-30 | Cons. | Operating income |
| Operating income | ¥5.4bn | 2024-07-01 → 2025-06-30 | Cons. | Operating income |
| Ordinary income | ¥5.5bn | 2025-07-01 → 2026-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥5.4bn | 2024-07-01 → 2025-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥4.4bn | 2023-07-01 → 2024-06-30v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.1bn | 2022-07-01 → 2023-06-30v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.8bn | 2021-07-01 → 2022-06-30v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥5.5bn | 2025-07-01 → 2026-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥5.4bn | 2024-07-01 → 2025-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.7bn | 2025-07-01 → 2026-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.6bn | 2024-07-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.9bn | 2023-07-01 → 2024-06-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.7bn | 2022-07-01 → 2023-06-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.4bn | 2021-07-01 → 2022-06-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥3.7bn | 2025-07-01 → 2026-06-30 | Cons. | Profit loss |
| Net income | ¥3.6bn | 2024-07-01 → 2025-06-30 | Cons. | Profit loss |
| Total assets | ¥39.5bn | at 2026-06-30 | Cons. | Assets |
| Total assets | ¥36.1bn | at 2025-06-30 | Cons. | Assets |
| Total assets | ¥32.0bn | at 2024-06-30v | Cons. | Total assets (5-year summary) |
| Total assets | ¥28.5bn | at 2023-06-30v | Cons. | Total assets (5-year summary) |
| Total assets | ¥26.2bn | at 2022-06-30v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥8.4bn | at 2026-06-30 | Cons. | Liabilities |
| Total liabilities | ¥8.0bn | at 2025-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥31.2bn | at 2026-06-30 | Cons. | Net assets |
| Net assets / equity | ¥28.1bn | at 2025-06-30 | Cons. | Net assets |
| Net assets / equity | ¥25.1bn | at 2024-06-30v | Cons. | Net assets |
| Net assets / equity | ¥20.9bn | at 2023-06-30v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥18.7bn | at 2022-06-30v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥17.2bn | at 2026-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥14.9bn | at 2025-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥14.4bn | at 2026-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.7bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥13.2bn | at 2024-06-30v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.0bn | at 2023-06-30v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥8.4bn | at 2022-06-30v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥7.6bn | 2025-07-01 → 2026-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.8bn | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.8bn | 2023-07-01 → 2024-06-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.7bn | 2022-07-01 → 2023-06-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.1bn | 2021-07-01 → 2022-06-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥8.2bn | 2025-07-01 → 2026-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.3bn | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.5bn | 2023-07-01 → 2024-06-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥304m | 2022-07-01 → 2023-06-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥477m | 2021-07-01 → 2022-06-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥189m | 2025-07-01 → 2026-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥939m | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥795m | 2023-07-01 → 2024-06-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥812m | 2022-07-01 → 2023-06-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥805m | 2021-07-01 → 2022-06-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥89 | 2025-07-01 → 2026-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥86.38 | 2024-07-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.14 | 2023-07-01 → 2024-06-30v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥67.83 | 2022-07-01 → 2023-06-30v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.55 | 2021-07-01 → 2022-06-30v | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥740.3 | at 2026-06-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥667.66 | at 2025-06-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥594.79 | at 2024-06-30v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥528.12 | at 2023-06-30v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥471.14 | at 2022-06-30v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 78.9% | at 2026-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.9% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.3% | at 2024-06-30v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.5% | at 2023-06-30v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.1% | at 2022-06-30v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 12.6% | 2025-07-01 → 2026-06-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 13.7% | 2024-07-01 → 2025-06-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.8% | 2023-07-01 → 2024-06-30v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 13.6% | 2022-07-01 → 2023-06-30v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 13.3% | 2021-07-01 → 2022-06-30v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 318 | at 2026-06-30 | Cons. | Number of employees |
| Employees | 304 | at 2025-06-30 | Cons. | Number of employees |
| Employees | 289 | at 2024-06-30v | Cons. | Number of employees |
| Employees | 297 | at 2023-06-30v | Cons. | Number of employees |
| Employees | 303 | at 2022-06-30v | Cons. | Number of employees |
| Revenue | ¥1.4bn | 2025-07-01 → 2026-06-30 | Standalone | Operating revenue1 |
| Revenue | ¥1.3bn | 2024-07-01 → 2025-06-30 | Standalone | Operating revenue1 |
| Revenue | ¥1.2bn | 2023-07-01 → 2024-06-30v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥1.1bn | 2022-07-01 → 2023-06-30v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥704m | 2021-07-01 → 2022-06-30v | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥749m | 2025-07-01 → 2026-06-30 | Standalone | Operating income |
| Operating income | ¥718m | 2024-07-01 → 2025-06-30 | Standalone | Operating income |
| Ordinary income | ¥764m | 2025-07-01 → 2026-06-30 | Standalone | Ordinary income |
| Ordinary income | ¥729m | 2024-07-01 → 2025-06-30 | Standalone | Ordinary income |
| Ordinary income | ¥631m | 2023-07-01 → 2024-06-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥515m | 2022-07-01 → 2023-06-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥89m | 2021-07-01 → 2022-06-30v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥764m | 2025-07-01 → 2026-06-30 | Standalone | Income before income taxes |
| Profit before tax | ¥729m | 2024-07-01 → 2025-06-30 | Standalone | Income before income taxes |
| Net income | ¥735m | 2025-07-01 → 2026-06-30 | Standalone | Profit loss |
| Net income | ¥700m | 2024-07-01 → 2025-06-30 | Standalone | Profit loss |
| Net income | ¥618m | 2023-07-01 → 2024-06-30v | Standalone | Net income loss (5-year summary) |
| Net income | ¥493m | 2022-07-01 → 2023-06-30v | Standalone | Net income loss (5-year summary) |
| Net income | ¥95m | 2021-07-01 → 2022-06-30v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥14.7bn | at 2026-06-30 | Standalone | Assets |
| Total assets | ¥13.4bn | at 2025-06-30 | Standalone | Assets |
| Total assets | ¥13.2bn | at 2024-06-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥11.4bn | at 2023-06-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥11.9bn | at 2022-06-30v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥2.4bn | at 2026-06-30 | Standalone | Liabilities |
| Total liabilities | ¥1.1bn | at 2025-06-30 | Standalone | Liabilities |
| Net assets / equity | ¥12.3bn | at 2026-06-30 | Standalone | Net assets |
| Net assets / equity | ¥12.2bn | at 2025-06-30 | Standalone | Net assets |
| Net assets / equity | ¥12.1bn | at 2024-06-30v | Standalone | Net assets |
| Net assets / equity | ¥10.3bn | at 2023-06-30v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥10.3bn | at 2022-06-30v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.3bn | at 2026-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.9bn | at 2025-06-30 | Standalone | Cash and deposits |
| EPS (basic) | ¥17.46 | 2025-07-01 → 2026-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥16.63 | 2024-07-01 → 2025-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.55 | 2023-07-01 → 2024-06-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥12.44 | 2022-07-01 → 2023-06-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥2.41 | 2021-07-01 → 2022-06-30v | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥18 | 2025-07-01 → 2026-06-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥16 | 2024-07-01 → 2025-06-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥13 | 2023-07-01 → 2024-06-30v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥12 | 2022-07-01 → 2023-06-30v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥11 | 2021-07-01 → 2022-06-30v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥292.11 | at 2026-06-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥290.65 | at 2025-06-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥287.02 | at 2024-06-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥260.32 | at 2023-06-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥258.89 | at 2022-06-30v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 83.9% | at 2026-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.5% | at 2025-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.4% | at 2024-06-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.4% | at 2023-06-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.9% | at 2022-06-30v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 6.0% | 2025-07-01 → 2026-06-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.8% | 2024-07-01 → 2025-06-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.5% | 2023-07-01 → 2024-06-30v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.8% | 2022-07-01 → 2023-06-30v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 0.9% | 2021-07-01 → 2022-06-30v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 42,119,980 | at 2026-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 42,119,980 | at 2025-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 42,119,980 | at 2024-06-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 39,619,980 | at 2023-06-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 39,619,980 | at 2022-06-30v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 22 | at 2026-06-30 | Standalone | Number of employees |
| Employees | 21 | at 2025-06-30 | Standalone | Number of employees |
| Employees | 19 | at 2024-06-30v | Standalone | Number of employees |
| Employees | 21 | at 2023-06-30v | Standalone | Number of employees |
| Employees | 22 | at 2022-06-30v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 55
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-07-01 → 2026-06-30 | ¥1m |
| Reconciling Itemsreconciling | depreciation | 2025-07-01 → 2026-06-30 | ¥990,000 |
| Reconciling Itemsreconciling | revenue | 2025-07-01 → 2026-06-30 | −¥1.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-07-01 → 2026-06-30 | −¥1.2bn |
| Reconciling Itemsreconciling | segment assets | at 2026-06-30 | ¥547m |
| Reconciling Itemsreconciling | segment profit | 2025-07-01 → 2026-06-30 | ¥40m |
| Drug Substance Sales Businessreportable segment | capex | 2025-07-01 → 2026-06-30 | ¥102m |
| Drug Substance Sales Businessreportable segment | depreciation | 2025-07-01 → 2026-06-30 | ¥107m |
| Drug Substance Sales Businessreportable segment | employees | at 2026-06-30 | 85 pure |
| Drug Substance Sales Businessreportable segment | revenue | 2025-07-01 → 2026-06-30 | ¥17.0bn |
| Drug Substance Sales Businessreportable segment | revenue external | 2025-07-01 → 2026-06-30 | ¥15.7bn |
| Drug Substance Sales Businessreportable segment | revenue intersegment | 2025-07-01 → 2026-06-30 | ¥1.2bn |
| Drug Substance Sales Businessreportable segment | segment assets | at 2026-06-30 | ¥20.8bn |
| Drug Substance Sales Businessreportable segment | segment profit | 2025-07-01 → 2026-06-30 | ¥3.3bn |
| Pharmaceutical Marketing Businessreportable segment | capex | 2025-07-01 → 2026-06-30 | ¥3.7bn |
| Pharmaceutical Marketing Businessreportable segment | depreciation | 2025-07-01 → 2026-06-30 | ¥507m |
| Pharmaceutical Marketing Businessreportable segment | employees | at 2026-06-30 | 211 pure |
| Pharmaceutical Marketing Businessreportable segment | revenue | 2025-07-01 → 2026-06-30 | ¥9.0bn |
| Pharmaceutical Marketing Businessreportable segment | revenue external | 2025-07-01 → 2026-06-30 | ¥9.0bn |
| Pharmaceutical Marketing Businessreportable segment | segment assets | at 2026-06-30 | ¥18.1bn |
| Pharmaceutical Marketing Businessreportable segment | segment profit | 2025-07-01 → 2026-06-30 | ¥2.1bn |
| —segment total | capex | 2025-07-01 → 2026-06-30 | ¥3.8bn |
| —segment total | depreciation | 2025-07-01 → 2026-06-30 | ¥614m |
| —segment total | employees | at 2026-06-30 | 296 pure |
| —segment total | revenue | 2025-07-01 → 2026-06-30 | ¥25.9bn |
| —segment total | revenue external | 2025-07-01 → 2026-06-30 | ¥24.7bn |
| —segment total | revenue intersegment | 2025-07-01 → 2026-06-30 | ¥1.2bn |
| —segment total | segment assets | at 2026-06-30 | ¥39.0bn |
| —segment total | segment profit | 2025-07-01 → 2026-06-30 | ¥5.4bn |
| Reconciling Itemsreconciling | capex | 2024-07-01 → 2025-06-30 | ¥2m |
| Reconciling Itemsreconciling | depreciation | 2024-07-01 → 2025-06-30 | ¥3m |
| Reconciling Itemsreconciling | revenue | 2024-07-01 → 2025-06-30 | −¥1.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-07-01 → 2025-06-30 | −¥1.3bn |
| Reconciling Itemsreconciling | segment assets | at 2025-06-30 | ¥1.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-07-01 → 2025-06-30 | ¥3m |
| Drug Substance Sales Businessreportable segment | capex | 2024-07-01 → 2025-06-30 | ¥71m |
| Drug Substance Sales Businessreportable segment | depreciation | 2024-07-01 → 2025-06-30 | ¥113m |
| Drug Substance Sales Businessreportable segment | revenue | 2024-07-01 → 2025-06-30 | ¥15.9bn |
| Drug Substance Sales Businessreportable segment | revenue external | 2024-07-01 → 2025-06-30 | ¥14.6bn |
| Drug Substance Sales Businessreportable segment | revenue intersegment | 2024-07-01 → 2025-06-30 | ¥1.3bn |
| Drug Substance Sales Businessreportable segment | segment assets | at 2025-06-30 | ¥19.5bn |
| Drug Substance Sales Businessreportable segment | segment profit | 2024-07-01 → 2025-06-30 | ¥3.2bn |
| Pharmaceutical Marketing Businessreportable segment | capex | 2024-07-01 → 2025-06-30 | ¥3.0bn |
| Pharmaceutical Marketing Businessreportable segment | depreciation | 2024-07-01 → 2025-06-30 | ¥576m |
| Pharmaceutical Marketing Businessreportable segment | revenue | 2024-07-01 → 2025-06-30 | ¥8.7bn |
| Pharmaceutical Marketing Businessreportable segment | revenue external | 2024-07-01 → 2025-06-30 | ¥8.7bn |
| Pharmaceutical Marketing Businessreportable segment | segment assets | at 2025-06-30 | ¥15.4bn |
| Pharmaceutical Marketing Businessreportable segment | segment profit | 2024-07-01 → 2025-06-30 | ¥2.1bn |
| —segment total | capex | 2024-07-01 → 2025-06-30 | ¥3.1bn |
| —segment total | depreciation | 2024-07-01 → 2025-06-30 | ¥689m |
| —segment total | revenue | 2024-07-01 → 2025-06-30 | ¥24.6bn |
| —segment total | revenue external | 2024-07-01 → 2025-06-30 | ¥23.3bn |
| —segment total | revenue intersegment | 2024-07-01 → 2025-06-30 | ¥1.3bn |
| —segment total | segment assets | at 2025-06-30 | ¥34.9bn |
| —segment total | segment profit | 2024-07-01 → 2025-06-30 | ¥5.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,415
| Item | Context | Value | Unit |
|---|---|---|---|
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_ReconcilingItemsMember | 1668000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration | 3077004000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 15717087000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 8961772000 | JPY |
| Revenues from external customers | CurrentYearDuration_ReportableSegmentsMember | 24678859000 | JPY |
| Revenues from external customers | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYearDuration | 24678859000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 1241246000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYearDuration_ReportableSegmentsMember | 1241246000 | JPY |
| Transactions with other segments | CurrentYearDuration_ReconcilingItemsMember | -1241246000 | JPY |
| Transactions with other segments | CurrentYearDuration | － | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 16958333000 | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 8961772000 | JPY |
| Net sales | CurrentYearDuration_ReportableSegmentsMember | 25920105000 | JPY |
| Net sales | CurrentYearDuration_ReconcilingItemsMember | -1241246000 | JPY |
| Net sales | CurrentYearDuration | 24678859000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 3312388000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 2123924000 | JPY |
| Operating income | CurrentYearDuration_ReportableSegmentsMember | 5436312000 | JPY |
| Operating income | CurrentYearDuration_ReconcilingItemsMember | 39859000 | JPY |
| Operating income | CurrentYearDuration | 5476171000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 20838906000 | JPY |
| Assets | CurrentYearInstant_jpcrp030000-asr_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 18147075000 | JPY |
| Assets | CurrentYearInstant_ReportableSegmentsMember | 38985982000 | JPY |
| Assets | CurrentYearInstant_ReconcilingItemsMember | 546727000 | JPY |
| Assets | CurrentYearInstant | 39532710000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 106608000 | JPY |
| Depreciation segment information | CurrentYearDuration_jpcrp030000-asr_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 506910000 | JPY |
| Depreciation segment information | CurrentYearDuration_ReportableSegmentsMember | 613518000 | JPY |
| Depreciation segment information | CurrentYearDuration_ReconcilingItemsMember | 990000 | JPY |
| Depreciation segment information | CurrentYearDuration | 614509000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_jpcrp030000-asr_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 101626000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_jpcrp030000-asr_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 3681722000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_ReportableSegmentsMember | 3783349000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_ReconcilingItemsMember | 1106000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration | 3784455000 | JPY |
| Cash and deposits | Prior1YearInstant_NonConsolidatedMember | 1857106000 | JPY |
| Cash and deposits | CurrentYearInstant_NonConsolidatedMember | 2328624000 | JPY |
| Prepaid expenses | Prior1YearInstant_NonConsolidatedMember | 8714000 | JPY |
| Prepaid expenses | CurrentYearInstant_NonConsolidatedMember | 12186000 | JPY |
| Accounts receivable other | Prior1YearInstant_NonConsolidatedMember | 58035000 | JPY |
| Accounts receivable other | CurrentYearInstant_NonConsolidatedMember | 63329000 | JPY |
| Short term loans receivable to subsidiaries and affiliates | Prior1YearInstant_NonConsolidatedMember | 422800000 | JPY |
| Short term loans receivable to subsidiaries and affiliates | CurrentYearInstant_NonConsolidatedMember | 22800000 | JPY |
| Current assets | Prior1YearInstant_NonConsolidatedMember | 2346656000 | JPY |
| Current assets | CurrentYearInstant_NonConsolidatedMember | 2426941000 | JPY |
| Buildings net | Prior1YearInstant_NonConsolidatedMember | 2168000 | JPY |
| Buildings net | CurrentYearInstant_NonConsolidatedMember | 1936000 | JPY |
| Vehicles net | Prior1YearInstant_NonConsolidatedMember | 0 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |